The cost of capital continues to challenge the biotech sector, but in today's tough market, you can still stand out. Whether you are telling your value story to investors or working with patient advocates – maximizing each interaction requires a deep understanding of your audiences & tailored messaging. Megan spoke with Doug Simon on "PR's Top Pros Talk" about how to articulate your value & rise above the rest.

For an early-stage biotech, data readouts carry big risks & potential rewards. Whether providing proof of concept, proving safety & tolerability, or clearing the way for final regulatory approval, clinical trial readouts are critical de-risking events. Communicating a clear, consistent message to your audiences is crucial to success, no matter what the data show. Read Megan’s step-by-step guide in MedCity News on how to effectively leverage clinical trial readouts.

Interested in diving deep into biotech comms & current industry trends? Listen to Megan on PR360! Prefer to catch the highlights? Drop in using this handy episode timeline:

• ⏱ 1:50 - The lasting impacts of COVID-19

• ⏱ 6:30 - Messaging for clinical trials

• ⏱ 11:20 - Accessing capital in a bear market

• ⏱ 14:15 - Healthcare delivery & education for gender-affirming care

• ⏱ 21:45 - AI in communication

All business developments - good & bad - have communication implications. An overabundance of clear, transparent messaging is important during times of change. When speaking with PR Week about the end to the Covid-19 public health emergency, Megan outlined helpful best practices.

On Fierce Biotech's The Top Line podcast, Sara Michelmore & Megan share market insights & strategic steps companies can take to prepare for upward momentum. Listen to learn what you can do today to position your company for a potential market swing.